Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Uterine Carcinosarcoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05559879
What this trial is testing

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Who this might be right for
Gynecologic CancerCarcinomaUterine Cancer+1 more
University of Alabama at Birmingham 37
Testing effectiveness (Phase 2)Study completedNCT00032162
What this trial is testing

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Who this might be right for
Cervical CancerEndometrial CancerFallopian Tube Cancer+2 more
AGO Study Group 63
Testing effectiveness (Phase 2)Study completedNCT01010126
What this trial is testing

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Who this might be right for
Adult Hepatocellular CarcinomaAdvanced Adult Hepatocellular CarcinomaEndometrial Serous Adenocarcinoma+42 more
National Cancer Institute (NCI) 252
Testing effectiveness (Phase 2)WithdrawnNCT04149275
What this trial is testing

Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

Who this might be right for
Carcinosarcoma of OvaryCarcinosarcoma of UterusCarcinosarcoma of Vagina
University of Alabama at Birmingham
Early research (Phase 1)UnknownNCT01454479
What this trial is testing

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Who this might be right for
Recurrent Endometrial Cancer
Hung-Hsueh Chou 24
Testing effectiveness (Phase 2)Looking for participantsNCT03686124
What this trial is testing

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Who this might be right for
Refractory CancerRecurrent CancerSolid Tumor, Adult+1 more
Immatics US, Inc. 375
Testing effectiveness (Phase 2)Study completedNCT01247571
What this trial is testing

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Who this might be right for
Recurrent Uterine Corpus SarcomaUterine Carcinosarcoma
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT03367741
What this trial is testing

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

Who this might be right for
Advanced Endometrial CarcinomaMetastatic Endometrial CarcinomaRecurrent Endometrial Carcinoma+2 more
National Cancer Institute (NCI) 82
Testing effectiveness (Phase 2)Study completedNCT03694262
What this trial is testing

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Who this might be right for
Endometrial CancerUterine Carcinosarcoma
Medical College of Wisconsin 30
Testing effectiveness (Phase 2)Ended earlyNCT05001282
What this trial is testing

Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinoma+22 more
Elucida Oncology 79
Testing effectiveness (Phase 2)Study completedNCT00003334
What this trial is testing

Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

Who this might be right for
Endometrial CancerFallopian Tube CancerOvarian Cancer+1 more
NYU Langone Health
Early research (Phase 1)Study completedNCT00006981
What this trial is testing

Immunotoxin Therapy in Treating Patients With Advanced Cancer

Who this might be right for
Cervical CancerFallopian Tube CancerHead and Neck Cancer+5 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT00474994
What this trial is testing

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

Who this might be right for
Adult Malignant Fibrous Histiocytoma of BoneDesmoid TumorEndometrial Cancer+3 more
Memorial Sloan Kettering Cancer Center 53
Large-scale testing (Phase 3)Study completedNCT00003128
What this trial is testing

Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus

Who this might be right for
Sarcoma
Gynecologic Oncology Group 166
Testing effectiveness (Phase 2)Ended earlyNCT01061606
What this trial is testing

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Who this might be right for
Recurrent Uterine SarcomaUterine Carcinosarcoma
National Cancer Institute (NCI) 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT03668340
What this trial is testing

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Who this might be right for
Uterine Cancer
Dana-Farber Cancer Institute 49
Large-scale testing (Phase 3)Ended earlyNCT01132547
What this trial is testing

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

Who this might be right for
Cancer
University of South Florida 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT03660826
What this trial is testing

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Who this might be right for
Endometrial AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous Adenocarcinoma+3 more
National Cancer Institute (NCI)
Not applicableLooking for participantsNCT06349642
What this trial is testing

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Who this might be right for
Early Stage Triple-Negative Breast CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Cervical Carcinoma+24 more
Mayo Clinic 324
Testing effectiveness (Phase 2)Study completedNCT00114218
What this trial is testing

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

Who this might be right for
Recurrent Uterine Corpus SarcomaUterine Carcinosarcoma
Gynecologic Oncology Group 28
Next Page
288